- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
First-Line Alectinib Yields Clinically Meaningful OS Benefit in Advanced ALK+ NSCLC
October 17th 2025, 6:31pm
First-line alectinib produced a clinically meaningful overall survival benefit in advanced ALK-positive non–small cell lung cancer.
Combining Durvalumab With BCG Yields Significant DFS Benefit vs BCG Alone in BCG-Naive NMIBC
October 17th 2025, 6:23pm
Durvalumab plus BCG induction and maintenance therapy yielded clinically meaningful improvement in DFS vs BCG induction and maintenance therapy alone in BCG-naive, high-risk NMIBC.
Zongertinib Displays Activity in Frontline HER2-Mutated NSCLC
October 17th 2025, 5:49pm
Zongertinib was effective for the first-line treatment of patients with treatment-naive HER2-mutated NSCLC.
Lenvatinib Plus Pembrolizumab and Chemotherapy Fails to Improve OS in Advanced ESCC
October 17th 2025, 5:23pm
First-line treatment with lenvatinib, pembrolizumab, and chemotherapy did not improve OS vs chemoimmunotherapy in patients with advanced ESCC.
Dr Necchi on Biomarker Data From the SunRISe-4 Trial of Gemcitabine Intravesical System Plus Cetrelimab in MIBC
October 17th 2025, 5:20pm
Andrea Necchi, MD, discusses the role of minimal residual disease assessment in the phase 2 SunRISe-4 trial evaluating TAR-200 plus cetrelimab in MIBC.
Dr Mok on Final OS Data From the ALEX Study Evaluating First-Line Alectinib in ALK+ NSCLC
October 17th 2025, 5:14pm
Tony S.K. Mok, BMSc, MD, FRCP(C), FRCP(Edin), FHKCP, FHKAM(Medicine), FASCO, shares final OS data from the phase 3 ALEX study in ALK-positive NSCLC.
Adjuvant Nivolumab Generates Long-Term DFS Benefit in Resected MIUC
October 17th 2025, 3:07pm
Five year follow up results from CheckMate 274 support adjuvant nivolumab as a standard of care for high-risk muscle-invasive urothelial carcinoma.
Dr Perol on Unmet Need for Post Immunotherapy Strategies in Lung Cancer
October 16th 2025, 3:20pm
Bridging the Gaps in Lung Cancer
Maurice Perol, MD, discusses the persistent unmet need for effective treatments following progression on immunotherapy in NSCLC.
Dr Peters on the Importance of Consensus Meetings to Address Clinical Ambiguity in Lung Cancer
October 16th 2025, 3:16pm
Bridging the Gaps in Lung Cancer
Solange Peters, MD, PhD, discusses the necessity of global consensus meetings to navigate clinical "gray zones" in lung cancer management.
Dr Passaro on the Role of MET in Guiding Treatment Strategies After EGFR TKI Progression in NSCLC
October 16th 2025, 12:51am
Bridging the Gaps in Lung Cancer
Antonio Passaro, MD, PhD, discusses testing methodologies and clinical trials for MET, the most studied resistance biomarker, following progression on EGFR TKIs.
Dr Faivre-Finn on Areas of Debate Surrounding Concurrent Chemoradiotherapy Plus IO in LS-SCLC
October 15th 2025, 11:54pm
Bridging the Gaps in Lung Cancer
Corinne Faivre-Finn, MD, discusses ongoing clinical debates regarding patient selection and optimal delivery of concurrent chemoradiotherapy followed by immunotherapy in LS-SCLC.
Countdown to ESMO 2025: Catch Up on OncLive’s Extensive Tumor-Specific Previews
October 13th 2025, 6:00pm
Preview the top lung, breast, GI, GU, gynecologic, and hematologic oncology abstracts and topics ahead of the 2025 ESMO Congress.
OncLive Poll Results Reveal Most Anticipated GI Cancer Abstracts and Subtypes Ahead of ESMO 2025
October 10th 2025, 1:00pm
See poll results highlighting the top gastrointestinal oncology abstracts and subtypes to watch at the 2025 ESMO Congress.
Poll Results Highlight Gynecologic Oncology Abstracts to Watch Ahead of ESMO 2025
October 10th 2025, 12:00pm
ESMO Congress: Gynecologic Cancers
See poll results highlighting the top gynecologic oncology abstracts and subtypes to watch at the 2025 ESMO Congress.
ESMO 2025 Will See Novel Agents Emerge and Standard Strategies Shift in GI Oncology
October 9th 2025, 2:00pm
Ahead of the 2025 ESMO Congress, GI cancer experts share the gastric cancer and CRC research they’re most looking forward to seeing at the meeting.
Inside the Most Anticipated Genitourinary Cancer Abstracts: What to Watch at ESMO 2025
October 8th 2025, 5:33pm
Experts in genitourinary oncology share key insights on the most anticipated data and abstracts expected to shape discussions at the 2025 ESMO Congress.
Poll: Vote on the Top Gynecologic and GI Cancer Abstracts/Topics to Watch at ESMO 2025
October 6th 2025, 6:00pm
Vote on the top abstracts and topics to watch in gynecologic and gastrointestinal oncology during the 2025 ESMO Congress.
OncLive Polls Highlight Top Votes on Anticipated Breast Cancer Abstracts at ESMO 2025
October 3rd 2025, 6:00pm
Breast cancer experts vote on their most anticipated abstracts on social media ahead of the 2025 ESMO Congress.
Experts Reflect on Ideas From MiBA 2025 That Will Propel the Future of AI-Driven Oncology
October 2nd 2025, 7:00pm
Oncology experts and AI advocates discuss insights about how AI can help manage tasks, keep up with evolving treatment practices, and improve patient care.
Inside the Most Anticipated Lung Cancer Abstracts: What to Expect From ESMO 2025
October 2nd 2025, 1:00pm
Ahead of the 2025 ESMO Congress, OncLive spoke with experts in lung cancer care to preview the most anticipated meeting abstracts.